INS and obesity due to melanocortin 4 receptor deficiency: MHO (approximately 30% of obesity) is characterized by obesity without obesity-related metabolic abnormalities, such as hyperglycemia, hypertension, dyslipidemia, and decreased insulin sensitivity (Bervoets and Massa, 2016).